Adverse dermatologic effects of erdafitinib in a patient with metastatic urothelial carcinoma

Authors

  • Megan Johnson Indiana University School of Medicine, Indianapolis, IN, USA Author
  • Marie Clark Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA Author
  • Carli Whittington Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA , Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA Author
  • Edita Newton Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA Author

DOI:

https://doi.org/10.25251/zj7ws289

Keywords:

erdafitinib, nails, oncology, onychomadesis, therapeutics

Abstract

Erdafitinib is a fibroblast growth factor receptor 1–4 inhibitor used for locally advanced or metastatic urothelial carcinoma in patients who have experienced disease progression after at least 1 prior systemic therapy. Various cutaneous side effects of erdafitinib have been reported, most commonly stomatitis and nail changes such as onycholysis, nail dystrophy, and paronychia. However, onychomadesis is a rarer nail toxicity that can cause significant discomfort and may necessitate treatment interruption. We present the case of a 61-year-old White man with metastatic urothelial carcinoma treated with 8 mg of erdafitinib daily who developed diffuse onychomadesis within a few months of initiating therapy. Awareness of the potential cutaneous side effects of erdafitinib and timely referral for specialty dermatologic care are important to allow treatment continuation.

References

1. Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023;e4:101204. doi:10.1016/j.xcrm.2023.101204. PMID:37757826

2. Deutsch A, McLellan BN. Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib. JAAD Case Rep. 2020;e6:569-571. doi:10.1016/j.jdcr.2020.04.013. PMID:32509951

3. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: Insight on the management of toxicities in clinical practice. Cancers (Basel). 2021;e13:2968. doi:10.3390/cancers13122968. PMID:34199304

4. Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT. Erdafitinib in the treatment of metastatic urothelial carcinoma. Oncology (Williston Park). 2023;e37:256-261. doi:10.46883/2023.25920998. PMID:37343207

5. Cohen PR. Acral erythema: A clinical review. Cutis. 1993;e51:175-179. PMID:8444048

6. Hueso L, Sanmartín O, Nagore E, et al. Eritema acral inducido por quimioterapia: estudio clínico e histopatológico de 44 casos [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]. Actas Dermosifiliogr. 2008;e99:281-290. doi:10.1016/S1578-2190(08)70252-X. PMID:18394404

7. Alessandrini A, Starace M, Cerè G, Brandi N, Piraccini BM. Management and outcome of taxane- induced nail side effects: Experience of 79 patients from a single centre. Skin Appendage Disord. 2019;e5:276-282. doi:10.1159/000497824. PMID:31559250

Downloads

Published

03/02/2026

Issue

Vol. 32 No. 1 (2026): Dermatology Online Journal

Section

Photo Vignette

License

Copyright (c) 2026 Megan Johnson, Marie Clark, Carli Whittington, Edita Newton (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.